Table of Contents
Managing insulin therapy effectively is one of the most critical aspects of living with Type 1 diabetes. Insulin treatment is essential for individuals with type 1 diabetes because the hallmark of type 1 diabetes is absent or near-absent β-cell function. Without proper insulin replacement, individuals face serious metabolic complications including hyperglycemia, ketoacidosis, and tissue catabolism. This comprehensive guide provides evidence-based strategies for optimizing insulin therapy, drawing from the latest clinical research and guidelines to help individuals with Type 1 diabetes achieve better glycemic control while minimizing complications.
The Foundation of Modern Insulin Therapy
Over the past four decades, evidence has accumulated supporting more intensive insulin replacement, using multiple daily injections of insulin or continuous subcutaneous administration through an insulin pump, as providing the best combination of effectiveness and safety for people with type 1 diabetes. The landmark Diabetes Control and Complications Trial (DCCT) fundamentally changed how we approach Type 1 diabetes management. In this landmark trial, lower A1C with intensive management (7.3%) led to ∼50% reductions in microvascular complications compared with 9.1% mean A1C in the conventional treatment arm over 6 years of treatment.
Achieving intensive glycemic goals during the active treatment period of the study had a persistent beneficial impact over the 20 years after the active treatment component of the study ended. This phenomenon, known as metabolic memory, underscores the importance of achieving good glycemic control early in the disease course. The benefits extend beyond microvascular complications to include reduced cardiovascular disease risk and improved overall mortality outcomes.
Understanding Different Types of Insulin
Successful insulin therapy requires understanding the pharmacokinetic and pharmacodynamic properties of different insulin formulations. The goal of insulin therapy in patients with either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) is to match as closely as possible normal physiologic insulin secretion to control fasting and postprandial plasma glucose. Modern insulin therapy uses a combination of different insulin types to mimic the body’s natural insulin secretion pattern.
Rapid-Acting Insulin Analogs
Rapid-Acting Insulin: It begins to work about 15 minutes after injection, peaks in about one or two hours after injection, and last between two to four hours. The three main rapid-acting insulin analogs available are insulin lispro (Humalog, Admelog, Lyumjev), insulin aspart (NovoLog, Fiasp), and insulin glulisine (Apidra). Review of the findings of PK/PD studies and clinical trials suggests that the three marketed rapid-acting analogues–insulin lispro, insulin aspart and insulin glulisine–are equally efficacious and safe.
These insulin analogs were developed by modifying the insulin molecule structure to alter absorption characteristics. With analogs, the insulin molecule structure is modified slightly to alter the pharmacokinetic properties of insulin, primarily affecting the absorption of the drug from the subcutaneous tissue. The modifications prevent the formation of hexamers that slow absorption, allowing for faster onset of action.
Rapid-acting analogues control these excursions better than human insulin because their pharmacokinetic/pharmacodynamic (PK/PD) profile is closer to that of meal-time endogenous insulin secretion. This improved profile translates to better postprandial glucose control and reduced risk of hypoglycemia between meals. The faster onset allows patients to inject immediately before or even after meals, providing greater flexibility compared to regular human insulin.
Short-Acting (Regular) Insulin
Regular or Short-Acting Insulin: It usually reaches the bloodstream within 30 minutes after injection, peaks anywhere from two to three hours after injection, and is effective for approximately three to six hours. Regular human insulin (Humulin R, Novolin R) has a slower onset than rapid-acting analogs because it forms hexamers after subcutaneous injection.
For this reason, regular insulin has a delayed onset of action of 30-60 minutes, and should be injected approximately 30 minutes before the meal to blunt the postprandial rise in blood glucose. While rapid-acting analogs have largely replaced regular insulin for mealtime coverage, regular insulin remains important because it is the only insulin formulation approved for intravenous administration, making it essential for hospital settings and diabetic ketoacidosis management.
Long-Acting Basal Insulin Analogs
Modifications of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) and three rapid-acting insulins (aspart, lispro, and glulisine) with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles. Long-acting basal insulins provide background insulin coverage throughout the day and night, mimicking the pancreas’s continuous basal insulin secretion.
Glargine has 2 arginine residues added at the end of the B chain at B31 and B32, and a substitution of glycine for asparagine at position A21, with an onset of action as early as 90 minutes. Both detemir and glargine have a duration of action up to 24 hours. These first-generation basal analogs represented a significant advance over NPH insulin by providing more predictable absorption and reduced risk of nocturnal hypoglycemia.
Second-generation basal insulins offer even longer duration of action. Degludec, a newer analogue (deletion of B30, with a palmitic acid attached to a γ-l-glutamic acid on B29), has onset after about 1 hour but can last up to 42 hours, the long duration of which confers possible benefits as a basal insulin. Insulin glargine U-300 (Toujeo) is a more concentrated formulation that also provides extended duration. In general, all long-acting preparations have a steady effect and minimal peak.
The development of basal insulins has been achieved by employing different means of protraction to prolong the rate of insulin absorption from the subcutaneous injection site into the circulation. Understanding these mechanisms helps clinicians select the most appropriate basal insulin for individual patients based on their lifestyle, glycemic patterns, and risk of hypoglycemia.
Intermediate-Acting Insulin (NPH)
NPH, or neutral protamine Hagedorn, is a suspension of regular insulin complexed with protamine that delays its absorption. NPH insulin has a characteristic cloudy appearance and typically has an onset of 2-4 hours, peaks at 4-10 hours, and lasts 12-18 hours. While NPH was once commonly used for basal coverage, it has largely been replaced by long-acting analogs in Type 1 diabetes management due to its pronounced peak and greater variability in absorption.
When compared with regular insulin and rapid-acting insulin analogs, such as insulin aspart, the pre-injection precipitation associated with NPH insulin achieves a flatter and longer PD profile. However, it is not sufficient to cover the entire 24-h period. The peak action of NPH increases the risk of hypoglycemia, particularly during the night when used as evening basal insulin.
Current Evidence-Based Treatment Recommendations
The American Diabetes Association updates its Standards of Care annually based on the latest scientific evidence. Treat most adults with type 1 diabetes with continuous subcutaneous insulin infusion or multiple daily doses of prandial (injected or inhaled) and basal insulin. This recommendation reflects decades of research demonstrating the superiority of intensive insulin therapy over conventional approaches.
For most adults with type 1 diabetes, insulin analogs (or inhaled insulin) are preferred over injectable human insulins to minimize hypoglycemia risk. The improved pharmacokinetic profiles of insulin analogs provide better glycemic control with reduced hypoglycemia compared to older human insulin formulations. This is particularly important given that hypoglycemia remains one of the major barriers to achieving optimal glycemic control.
Multiple Daily Injection Regimens
A basal-bolus insulin regimen using multiple daily injections (MDI) is the foundation of intensive insulin therapy for many people with Type 1 diabetes. Insulin replacement plans typically consist of basal insulin, mealtime insulin, and correction insulin. This approach attempts to mimic physiologic insulin secretion by providing continuous background insulin coverage with long-acting insulin and mealtime boluses with rapid-acting insulin.
A typical MDI regimen includes one or two daily injections of long-acting basal insulin (such as glargine, detemir, or degludec) combined with rapid-acting insulin before each meal. Most patients with T1D on multiple daily injection therapy take 1 to 2 injections of basal insulin daily and 3 or more injections of ultra-rapid- or rapid-acting insulin daily. The basal insulin dose is adjusted to maintain target glucose levels during fasting periods, while mealtime insulin doses are calculated based on carbohydrate intake and current blood glucose levels.
Insulin Pump Therapy
Continuous subcutaneous insulin infusion (CSII) through an insulin pump offers an alternative to multiple daily injections. In the treatment of T1D, the exception to needing long-acting insulin is when using an insulin pump. Because pumps constantly infuse rapid-acting insulin (basal rate), these patients do not require use of a long-acting formulation. Insulin pumps deliver rapid-acting insulin continuously at programmed basal rates and allow users to deliver bolus doses for meals and corrections.
Pump therapy offers several advantages including the ability to program multiple basal rates throughout the day, deliver insulin in very small increments, and calculate bolus doses based on programmed insulin-to-carbohydrate ratios and correction factors. This flexibility can be particularly beneficial for individuals with variable schedules, dawn phenomenon, or frequent hypoglycemia.
Automated Insulin Delivery Systems
Automated insulin delivery (AID) systems represent the cutting edge of Type 1 diabetes technology. Automated insulin delivery (AID) systems are safe and effective for people with type 1 diabetes. These systems integrate an insulin pump, continuous glucose monitor, and control algorithm that automatically adjusts insulin delivery based on real-time glucose readings.
Randomized controlled trials and real-world studies have demonstrated the ability of commercially available systems to improve achievement of glycemic goals while reducing the risk of hypoglycemia. AID systems reduce the burden of diabetes management by automating many insulin dosing decisions, particularly overnight basal insulin adjustments that were previously challenging to optimize.
AID systems are preferred and should be considered for individuals with type 1 diabetes who are capable of using the device safely (either by themselves or with a caregiver) to improve time in range and reduce A1C and hypoglycemia. The latest ADA guidelines emphasize that AID systems should be considered for most people with Type 1 diabetes, representing a shift toward technology-enabled care as the preferred approach when feasible.
Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia. As these systems continue to evolve, they are becoming more sophisticated with improved algorithms, smaller devices, and reduced user burden.
The Critical Role of Continuous Glucose Monitoring
Continuous glucose monitoring has revolutionized diabetes management by providing real-time glucose data and trend information. Continuous glucose monitoring improves outcomes with injected or infused insulin and is superior to blood glucose monitoring. CGM devices measure interstitial glucose levels continuously throughout the day and night, providing users with current glucose readings, trend arrows, and alerts for high and low glucose levels.
Recommendation 7.15 was modified to support the use of real-time CGM (rtCGM) and intermittently scanned CGM (isCGM) for youth and adults with diabetes (type 1 or type 2) on any type of insulin therapy based on the most recent literature. This expanded recommendation reflects growing evidence that CGM benefits extend to all individuals using insulin, not just those on intensive regimens.
Types of CGM Systems
There are two main categories of CGM systems: real-time CGM (rtCGM) and intermittently scanned CGM (isCGM). Real-time CGM systems continuously transmit glucose data to a receiver or smartphone, providing alerts for high and low glucose levels. These systems include Dexcom G6 and G7, Medtronic Guardian, and others. Intermittently scanned CGM, such as the FreeStyle Libre system, requires users to scan a sensor to view glucose readings but does not provide automatic alerts (though newer versions have added optional alarms).
Both types of CGM provide valuable information about glucose trends and patterns that fingerstick blood glucose monitoring cannot capture. The ability to see glucose trends helps users make more informed decisions about insulin dosing, food choices, and activity. CGM data also reveals patterns such as overnight hypoglycemia or post-meal hyperglycemia that might otherwise go undetected.
Using CGM Data to Optimize Insulin Therapy
CGM provides several key metrics that help assess glycemic control beyond A1C. Time in range (TIR), defined as the percentage of time glucose is between 70-180 mg/dL, has emerged as an important outcome measure. Higher time in range is associated with reduced risk of diabetes complications. CGM also measures time below range (hypoglycemia) and time above range (hyperglycemia), providing a more complete picture of glycemic control.
The glucose management indicator (GMI) estimates A1C based on average CGM glucose readings. Coefficient of variation (CV) measures glucose variability, with lower values indicating more stable glucose levels. These metrics help clinicians and patients identify specific problems with insulin regimens and make targeted adjustments.
CGM trend arrows indicate the direction and speed of glucose changes, allowing users to make proactive insulin adjustments. For example, a rapidly rising glucose after a meal might prompt an additional correction dose, while a rapidly falling glucose might lead to consuming carbohydrates to prevent hypoglycemia. This real-time feedback enables more precise insulin dosing than was possible with periodic fingerstick testing alone.
Calculating and Adjusting Insulin Doses
Proper insulin dosing requires understanding several key concepts and calculations. To improve glycemic outcomes and quality of life and to minimize hypoglycemia risk, most adults with type 1 diabetes should receive education on how to match mealtime insulin doses to carbohydrate intake and fat and protein intake depending on the person’s or caregiver’s needs or preferences. Individualized insulin dosing is essential for achieving optimal glycemic control while minimizing hypoglycemia risk.
Determining Total Daily Insulin Dose
The total daily insulin dose (TDD) varies considerably among individuals based on factors including body weight, insulin sensitivity, physical activity level, and stage of disease. A common starting point for calculating TDD in Type 1 diabetes is 0.5-0.6 units per kilogram of body weight per day, though this can range from 0.3 to over 1.0 units/kg/day depending on individual factors.
During the “honeymoon period” shortly after diagnosis, when some residual beta-cell function remains, insulin requirements may be lower (0.3-0.5 units/kg/day). As the disease progresses and endogenous insulin production ceases, requirements typically increase. Adolescents often require higher doses due to insulin resistance associated with puberty, sometimes exceeding 1.0 units/kg/day. Physical activity level, diet composition, and other medications also influence insulin requirements.
Basal-Bolus Insulin Distribution
In a typical basal-bolus regimen, approximately 40-50% of the total daily insulin dose is given as basal insulin, with the remaining 50-60% divided among mealtime boluses. This distribution can vary based on individual eating patterns and insulin sensitivity. Someone who eats larger meals might require a higher proportion of bolus insulin, while someone with significant insulin resistance overnight might need more basal insulin.
For individuals using insulin pumps, basal rates can be programmed to vary throughout the day to match changing insulin needs. Many people require higher basal rates in the early morning hours to counteract the dawn phenomenon, when hormones cause blood glucose to rise. Basal rates may need to be lower during periods of increased physical activity or higher during illness or stress.
Carbohydrate Counting and Insulin-to-Carbohydrate Ratios
Carbohydrate counting is the foundation of mealtime insulin dosing in Type 1 diabetes. The insulin-to-carbohydrate ratio (I:C ratio) indicates how many grams of carbohydrate are covered by one unit of rapid-acting insulin. A common starting I:C ratio is 1:10 to 1:15, meaning one unit of insulin covers 10-15 grams of carbohydrate, though individual ratios vary widely.
To calculate a starting I:C ratio, the “500 rule” is often used: divide 500 by the total daily insulin dose. For example, if someone uses 50 units of insulin per day, their estimated I:C ratio would be 500 ÷ 50 = 10, or 1:10 (one unit per 10 grams of carbohydrate). This is only a starting point and must be adjusted based on post-meal glucose responses.
I:C ratios often vary throughout the day due to changing insulin sensitivity. Many people are more insulin resistant in the morning and require a stronger ratio (such as 1:8) for breakfast, while being more insulin sensitive later in the day and needing a weaker ratio (such as 1:15) for dinner. CGM data showing post-meal glucose patterns helps identify when ratio adjustments are needed.
Correction Factor (Insulin Sensitivity Factor)
They should also be taught how to modify the insulin dose (correction dose) based on concurrent glycemia, glycemic trends (if available), sick-day management, and anticipated physical activity. The correction factor, also called insulin sensitivity factor (ISF), indicates how much one unit of rapid-acting insulin will lower blood glucose. A correction factor of 50 means one unit of insulin will lower blood glucose by approximately 50 mg/dL.
The “1800 rule” (or “1500 rule” for more insulin-resistant individuals) provides a starting estimate: divide 1800 by the total daily insulin dose. For someone using 50 units daily, the estimated correction factor would be 1800 ÷ 50 = 36 mg/dL per unit. Like I:C ratios, correction factors must be individualized and may vary throughout the day.
When calculating a correction dose, subtract the target glucose from the current glucose and divide by the correction factor. For example, if current glucose is 220 mg/dL, target is 120 mg/dL, and correction factor is 50, the correction dose would be (220 – 120) ÷ 50 = 2 units. This correction dose would be added to any mealtime insulin needed.
Insulin on Board and Stacking
Insulin on board (IOB), also called active insulin, refers to insulin from previous boluses that is still working in the body. Rapid-acting insulin analogs typically have a duration of action of 3-5 hours, meaning insulin from a previous dose continues to lower glucose during this time. Failing to account for IOB when giving correction doses can lead to “insulin stacking” and hypoglycemia.
Most insulin pumps and some diabetes management apps automatically calculate IOB and subtract it from recommended correction doses. For those calculating manually, a conservative approach is to avoid giving correction doses within 3-4 hours of the previous bolus unless glucose is significantly elevated and rising. Understanding IOB is particularly important when correcting high glucose levels multiple times in succession.
Adjusting for Fat and Protein
While carbohydrates have the most immediate impact on blood glucose, meals high in fat and protein can also affect glucose levels, though more slowly and over a longer period. High-fat meals can delay carbohydrate absorption and cause prolonged elevation in blood glucose several hours after eating. High-protein meals can be converted to glucose through gluconeogenesis, particularly when carbohydrate intake is low.
Some individuals using insulin pumps address this by using extended or dual-wave boluses that deliver insulin over several hours for high-fat or high-protein meals. Those using injections might take a small additional dose 1-2 hours after a high-fat meal if glucose begins rising. The impact of fat and protein varies considerably among individuals and requires experimentation to determine optimal dosing strategies.
Recognizing and Avoiding Overbasalization
Overbasalization occurs when basal insulin doses are too high, leading to problems with glycemic control and increased hypoglycemia risk. Recommendation 9.27 was revised to remove consideration of basal insulin doses exceeding 0.5 units/kg/day as evidence of overbasalization. Instead, signs of overbasalization including significant bedtime-to-morning or postprandial-to-preprandial glucose differential, occurrences of hypoglycemia (aware or unaware), and high glycemic variability should be used.
Signs of overbasalization include needing to eat to prevent hypoglycemia between meals, significant drops in glucose overnight, and glucose levels that are lower before meals than after meals. When basal insulin is too high, individuals may compensate by eating more frequently or taking less mealtime insulin, leading to suboptimal overall control.
To assess basal insulin adequacy, fasting tests can be performed by skipping a meal and monitoring glucose levels. If glucose drops significantly during the fasting period, basal insulin may be too high. If glucose rises substantially, basal insulin may be insufficient. Properly dosed basal insulin should maintain relatively stable glucose levels during fasting periods without causing hypoglycemia.
Managing Hypoglycemia
Hypoglycemia remains one of the most significant challenges in intensive insulin therapy. However, intensive therapy was associated with a higher rate of severe hypoglycemia than conventional treatment (62 compared with 19 episodes per 100 person-years of therapy). While modern insulin analogs and CGM technology have reduced hypoglycemia risk compared to older treatment approaches, preventing and managing low blood glucose remains a critical skill.
Recognizing Hypoglycemia Symptoms
Hypoglycemia symptoms fall into two categories: autonomic (neurogenic) symptoms caused by the body’s counter-regulatory response, and neuroglycopenic symptoms caused by insufficient glucose delivery to the brain. Autonomic symptoms include shakiness, sweating, rapid heartbeat, anxiety, and hunger. Neuroglycopenic symptoms include confusion, difficulty concentrating, blurred vision, weakness, and in severe cases, loss of consciousness or seizures.
Hypoglycemia unawareness occurs when individuals lose the ability to recognize early warning symptoms, often due to recurrent hypoglycemia. This dangerous condition increases the risk of severe hypoglycemia. CGM with predictive low glucose alerts can be particularly valuable for people with hypoglycemia unawareness, providing warnings before glucose drops to dangerous levels.
Treating Hypoglycemia: The Rule of 15
The “rule of 15” provides a structured approach to treating hypoglycemia: consume 15 grams of fast-acting carbohydrate, wait 15 minutes, recheck blood glucose, and repeat if still below 70 mg/dL. Fast-acting carbohydrates include glucose tablets, juice, regular soda, or honey. These are preferred over foods containing fat or protein, which slow carbohydrate absorption.
After glucose returns to normal, consuming a snack with protein and complex carbohydrates can help prevent recurrent hypoglycemia, especially if the next meal is more than an hour away. It’s important to avoid over-treating hypoglycemia, which can lead to rebound hyperglycemia and a cycle of glucose fluctuations.
Severe hypoglycemia requiring assistance from another person requires glucagon administration. Glucagon emergency kits are available as injections or nasal spray formulations. Family members, roommates, and coworkers should be trained on when and how to administer glucagon. After glucagon administration, emergency medical services should be contacted, and the person should consume carbohydrates once able to swallow safely.
Preventing Hypoglycemia
Prevention strategies include appropriate insulin dosing, regular meal timing, monitoring glucose before and during physical activity, and using CGM alerts. When planning exercise, insulin doses may need to be reduced or carbohydrates consumed to prevent activity-induced hypoglycemia. Alcohol consumption increases hypoglycemia risk by impairing the liver’s ability to produce glucose, requiring extra caution and glucose monitoring.
Reviewing patterns of hypoglycemia with healthcare providers helps identify causes and implement preventive strategies. Recurrent hypoglycemia at the same time of day suggests insulin doses need adjustment. Unpredictable hypoglycemia may indicate issues with carbohydrate counting, insulin timing, or other factors requiring problem-solving.
Physical Activity and Insulin Adjustments
Physical activity affects blood glucose through multiple mechanisms. Exercise increases insulin sensitivity and glucose uptake by muscles, which can lower blood glucose during and for many hours after activity. However, high-intensity exercise can initially raise blood glucose due to stress hormone release. Understanding these effects is essential for making appropriate insulin adjustments.
Strategies for Aerobic Exercise
For planned aerobic exercise (such as running, cycling, or swimming), several strategies can prevent hypoglycemia. Reducing the insulin dose active during exercise is often effective. For those on pumps, temporary basal rate reductions of 50-80% starting 60-90 minutes before exercise can prevent lows. For those on injections, reducing the rapid-acting insulin dose at the meal before exercise by 25-50% may be appropriate.
Alternatively, consuming additional carbohydrates before or during exercise can offset increased glucose utilization. The amount needed depends on exercise intensity and duration, baseline glucose level, and individual response. Starting with 15-30 grams of carbohydrate per hour of moderate-intensity exercise is a reasonable guideline, adjusted based on experience.
Monitoring glucose before, during (for prolonged exercise), and after activity helps identify patterns and refine strategies. CGM is particularly valuable during exercise, showing real-time glucose trends and allowing proactive adjustments. Glucose should ideally be above 90-100 mg/dL before starting exercise, with carbohydrates consumed if lower.
Managing High-Intensity and Resistance Exercise
High-intensity interval training and resistance exercise can cause blood glucose to rise initially due to release of counter-regulatory hormones like adrenaline and cortisol. This may require small correction doses after exercise. However, delayed hypoglycemia can occur hours later as muscles replenish glycogen stores, requiring vigilance and possible insulin dose reductions for subsequent meals or overnight basal rates.
The glucose response to exercise varies considerably among individuals and even within the same person on different days. Keeping records of exercise type, duration, insulin adjustments, and glucose responses helps develop personalized strategies. Working with a diabetes educator or exercise physiologist familiar with Type 1 diabetes can provide valuable guidance.
Sick Day Management
Illness significantly affects insulin requirements and blood glucose control. Stress hormones released during illness increase insulin resistance, often causing blood glucose to rise even when eating less than usual. Conversely, vomiting or diarrhea can lead to hypoglycemia and dehydration. Having a sick day management plan is essential for preventing diabetic ketoacidosis and other complications.
Insulin Adjustments During Illness
Basal insulin should never be stopped during illness, even if unable to eat, as this can lead to diabetic ketoacidosis. In fact, basal insulin doses often need to be increased by 10-20% or more during illness to counteract increased insulin resistance. Frequent glucose monitoring (every 2-4 hours) helps guide insulin adjustments.
If blood glucose is elevated, correction doses of rapid-acting insulin should be given according to the usual correction factor, with doses repeated every 3-4 hours if glucose remains high. If unable to eat regular meals, consuming easily digestible carbohydrates like juice, crackers, or soup helps prevent hypoglycemia while providing some nutrition.
Monitoring for Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is a life-threatening complication that can develop during illness when insulin levels are insufficient. Warning signs include persistent hyperglycemia (glucose above 250 mg/dL), presence of ketones in urine or blood, nausea and vomiting, abdominal pain, fruity-smelling breath, rapid breathing, and confusion.
Ketone testing should be performed when blood glucose is above 250 mg/dL during illness or when feeling unwell. Urine ketone strips or blood ketone meters provide this information. If moderate or large ketones are present along with high blood glucose, contact with healthcare providers is urgent. DKA requires immediate medical attention and often hospitalization for intravenous insulin and fluid replacement.
When to Seek Medical Attention
Medical attention should be sought if unable to keep down fluids for more than 6 hours, if moderate or large ketones persist despite correction insulin doses, if blood glucose remains above 300 mg/dL despite multiple correction doses, or if experiencing symptoms of DKA. Having clear guidelines for when to call healthcare providers or go to the emergency department should be part of every sick day plan.
Special Considerations for Insulin Storage and Administration
Proper insulin storage and injection technique are often overlooked aspects of insulin therapy that can significantly impact effectiveness. Insulin is a protein that can be damaged by extreme temperatures, affecting its potency and glucose-lowering ability.
Insulin Storage Guidelines
Unopened insulin vials, pens, and cartridges should be stored in the refrigerator at 36-46°F (2-8°C) until the expiration date printed on the package. Insulin should never be frozen; if frozen, it must be discarded. Once opened, most insulin can be kept at room temperature (below 86°F or 30°C) for 28 days, though specific products may vary. Check package inserts for exact storage requirements.
Insulin should be protected from direct sunlight and extreme heat. In hot weather, insulin should be kept in a cooler (but not directly on ice) when outdoors. In cold weather, insulin should be kept close to the body to prevent freezing. Insulin that has been exposed to extreme temperatures, appears cloudy (when it should be clear), or has particles or discoloration should be discarded.
Injection Site Rotation
Rotating injection sites prevents lipohypertrophy (fatty lumps) and lipoatrophy (loss of fat tissue) that can develop with repeated injections in the same area. These changes in subcutaneous tissue can affect insulin absorption, leading to unpredictable glucose control. Common injection sites include the abdomen, thighs, buttocks, and backs of arms.
The abdomen typically provides the most consistent absorption and is often preferred for rapid-acting insulin. Injections should be at least one inch away from the navel and any scars or moles. Within each body area, injection sites should be rotated systematically, with at least one inch between injection sites. Regularly inspecting injection sites for lumps, bumps, or changes in skin texture helps identify problem areas early.
Proper Injection Technique
Proper injection technique ensures insulin is delivered into subcutaneous tissue rather than muscle or intradermally. For most people, injections can be given at a 90-degree angle without pinching the skin, especially when using shorter needles (4-6 mm). Thinner individuals or children may need to pinch the skin and inject at a 45-degree angle to avoid intramuscular injection.
After inserting the needle, insulin should be injected slowly. When using insulin pens, the needle should remain in the skin for 5-10 seconds after pressing the injection button to ensure the full dose is delivered. Removing the needle too quickly can result in insulin leaking out, leading to underdosing.
Needle reuse is not recommended by manufacturers, as needles become dull and can cause more pain and tissue damage with repeated use. However, if needles are reused due to cost or access issues, they should be recapped carefully and used only by the same person. Needles should be disposed of in a sharps container, not regular trash.
Working with Your Healthcare Team
Insulin treatment plans and insulin-taking behaviors should be reevaluated at regular intervals (e.g., every 3–6 months) and adjusted to incorporate specific factors. Successful insulin therapy requires ongoing collaboration with a healthcare team that typically includes an endocrinologist or primary care provider, diabetes educator, dietitian, and potentially a mental health professional.
Regular Follow-Up and Monitoring
Regular appointments allow healthcare providers to review glucose data, assess A1C levels, screen for complications, and adjust treatment plans. Most people with Type 1 diabetes should see their diabetes care provider every 3-4 months, or more frequently if experiencing problems with glycemic control or other issues. A1C testing at each visit provides information about average glucose control over the previous 2-3 months.
Downloading and reviewing CGM or blood glucose meter data before appointments helps identify patterns and problems. Many diabetes management apps and platforms allow data sharing with healthcare providers, facilitating remote monitoring and adjustments between visits. Coming to appointments with specific questions or concerns ensures important issues are addressed.
Diabetes Self-Management Education and Support
Diabetes self-management education and support (DSMES) programs provide structured education on all aspects of diabetes care, including insulin management, carbohydrate counting, glucose monitoring, and problem-solving. These programs are typically led by certified diabetes care and education specialists (CDCES) and have been shown to improve glycemic control and quality of life.
DSMES is particularly valuable at diagnosis, when starting new technologies like insulin pumps or CGM, during life transitions, and when experiencing challenges with diabetes management. Insurance typically covers DSMES services, though the extent of coverage varies. The American Diabetes Association and American Association of Diabetes Educators maintain directories of accredited programs and certified educators.
Mental Health Support
The psychological burden of Type 1 diabetes is significant, with higher rates of depression, anxiety, and diabetes distress compared to the general population. The constant demands of insulin management, glucose monitoring, and carbohydrate counting can be overwhelming. Diabetes burnout, characterized by feeling overwhelmed and wanting to give up on diabetes management, is common.
Mental health support should be an integral part of diabetes care. Screening for depression, anxiety, and diabetes distress should occur regularly, with referrals to mental health professionals when needed. Psychologists and therapists with expertise in chronic illness can provide valuable support. Peer support groups, either in-person or online, connect individuals with others facing similar challenges.
Emerging Technologies and Future Directions
The field of Type 1 diabetes management continues to evolve rapidly, with new technologies and treatment approaches emerging regularly. Understanding these developments helps individuals make informed decisions about their care and anticipate future options.
Advanced Automated Insulin Delivery Systems
Next-generation AID systems are becoming increasingly sophisticated, with improved algorithms that require less user input and provide tighter glucose control. Some systems now offer fully closed-loop control for meals, automatically delivering insulin based on glucose trends without requiring carbohydrate counting. Others integrate with smartwatches and provide more discreet monitoring and control.
Dual-hormone systems that deliver both insulin and glucagon are in development, potentially offering even better glucose control by both lowering and raising glucose as needed. These systems may be particularly beneficial for preventing hypoglycemia during exercise and overnight.
Ultra-Rapid Insulin Analogs
Ultra-rapid-acting insulin formulations with even faster onset than current rapid-acting analogs are now available. It is possible that the ultra-rapid-acting insulins may become the preferred form for use in insulin pumps since they are excellent at bringing down high blood glucose levels quickly. These insulins may provide better postprandial glucose control and more flexibility in injection timing relative to meals.
Inhaled Insulin
In 2015 an inhaled insulin product, Afrezza, became available in the U.S. Afrezza is a rapid-acting inhaled insulin that is administered at the beginning of each meal and can be used by adults with type 1 or type 2 diabetes. Inhaled insulin offers a needle-free option for mealtime insulin coverage, though it must be used in combination with injectable basal insulin. Afrezza is not a substitute for long-acting insulin. Afrezza must be used in combination with injectable long-acting insulin in patients with type 1 diabetes and in type 2 patients who use long-acting insulin.
While inhaled insulin provides an alternative for those with needle phobia or injection site issues, it requires pulmonary function testing before starting and periodically during use. It is not appropriate for people with chronic lung disease, smokers, or those who recently quit smoking.
Immunotherapy and Beta Cell Replacement
Research into disease-modifying therapies aims to preserve or restore beta cell function. Teplizumab, an immunotherapy drug, has been approved for delaying the onset of stage 3 Type 1 diabetes in individuals with stage 2 disease (positive autoantibodies with dysglycemia but not yet meeting diabetes criteria). Other immunotherapies are being studied for newly diagnosed Type 1 diabetes.
Beta cell replacement through islet cell or pancreas transplantation can restore insulin production and eliminate the need for exogenous insulin. However, these procedures require lifelong immunosuppression and are typically reserved for individuals with severe hypoglycemia unawareness or those receiving kidney transplants. Research into encapsulated islet cells that don’t require immunosuppression and stem cell-derived beta cells continues to advance.
Practical Tips for Successful Insulin Management
Beyond the technical aspects of insulin therapy, several practical strategies can improve diabetes management and quality of life.
Keeping Detailed Records
While CGM and insulin pumps automatically record much data, keeping notes about factors affecting glucose control provides valuable context. Recording unusual meals, exercise, illness, stress, menstrual cycles, and other variables helps identify patterns and troubleshoot problems. Many diabetes apps allow adding notes and tags to glucose readings, making pattern recognition easier.
Planning Ahead
Always carrying backup supplies prevents emergencies. This includes extra insulin, syringes or pen needles, glucose tablets or other fast-acting carbohydrates, glucagon, and backup batteries for pumps and CGM receivers. When traveling, insulin and supplies should be carried in carry-on luggage, never checked baggage. Having a letter from a healthcare provider explaining the need for diabetes supplies and devices can be helpful when going through security.
Planning for time zone changes during travel requires adjusting insulin doses and timing. When traveling east (shorter day), less insulin may be needed. When traveling west (longer day), more insulin may be required. Working with healthcare providers before travel helps develop a safe adjustment plan.
Communicating with Others
Educating family members, friends, coworkers, and teachers about Type 1 diabetes and how to help in emergencies is important for safety. People who spend significant time with someone with Type 1 diabetes should know the signs of hypoglycemia, how to administer glucagon, and when to call emergency services. Medical alert jewelry identifying Type 1 diabetes can be lifesaving in emergencies when unable to communicate.
Addressing Cost Barriers
The high cost of insulin and diabetes supplies is a significant barrier for many people. Patient assistance programs offered by insulin manufacturers can provide free or reduced-cost insulin for those who qualify. Nonprofit organizations like the American Diabetes Association maintain resources about financial assistance programs. Generic insulin options and biosimilar insulins offer lower-cost alternatives, though they may have different pharmacokinetic profiles than brand-name analogs.
Working with social workers or patient navigators can help identify insurance coverage options, patient assistance programs, and other resources. Never rationing insulin due to cost is critical, as this can lead to life-threatening complications. Healthcare providers should be informed about cost concerns so they can help find solutions.
Key Takeaways for Optimal Insulin Therapy
Effective insulin therapy in Type 1 diabetes requires a comprehensive approach that integrates multiple elements:
- Use intensive insulin therapy: Multiple daily injections or insulin pump therapy combined with frequent glucose monitoring provides the best outcomes for preventing complications.
- Prefer insulin analogs: Rapid-acting and long-acting insulin analogs offer improved pharmacokinetic profiles compared to older human insulins, with better glycemic control and reduced hypoglycemia risk.
- Embrace continuous glucose monitoring: CGM provides invaluable real-time data and trend information that enables more precise insulin dosing and helps prevent both hypoglycemia and hyperglycemia.
- Consider automated insulin delivery: AID systems represent the current standard of care when feasible, improving time in range while reducing the burden of diabetes management.
- Master carbohydrate counting: Accurate carbohydrate counting and understanding insulin-to-carbohydrate ratios are fundamental skills for matching insulin doses to food intake.
- Individualize insulin doses: Insulin requirements vary widely among individuals and within the same person over time. Regular assessment and adjustment of basal rates, I:C ratios, and correction factors are essential.
- Prevent and manage hypoglycemia: Understanding hypoglycemia symptoms, treatment strategies, and prevention approaches is critical for safety and quality of life.
- Adjust for activity and illness: Physical activity and illness significantly affect insulin requirements. Having strategies for these situations prevents dangerous glucose excursions.
- Work with a healthcare team: Regular follow-up with diabetes specialists, educators, and other team members ensures optimal care and provides support for the challenges of diabetes management.
- Stay informed about advances: The field of diabetes technology and treatment continues to evolve rapidly. Staying current with new options enables informed decision-making about care.
Conclusion
Insulin therapy for Type 1 diabetes has advanced dramatically from the early days of animal-derived insulin and once-daily injections. Modern insulin analogs, sophisticated delivery systems, continuous glucose monitoring, and automated insulin delivery have transformed what is possible in terms of glycemic control and quality of life. The evidence is clear that intensive insulin therapy reduces the risk of both microvascular and macrovascular complications, with benefits that persist for decades.
However, optimal insulin therapy requires more than just access to the latest technology. It demands education, skill development, problem-solving abilities, and ongoing support. Understanding the pharmacology of different insulin types, mastering dose calculation, recognizing patterns in glucose data, and knowing how to adjust therapy for various situations are all essential competencies.
The psychological and emotional aspects of living with Type 1 diabetes and managing intensive insulin therapy should not be underestimated. The constant vigilance required, fear of hypoglycemia, and burden of decision-making can be overwhelming. Access to mental health support and peer connections is as important as access to insulin and technology.
Looking forward, continued advances in insulin formulations, delivery systems, and glucose monitoring promise to make diabetes management increasingly effective and less burdensome. Immunotherapies and beta cell replacement approaches may eventually prevent or cure Type 1 diabetes. Until then, applying current evidence-based practices for insulin therapy offers the best opportunity for people with Type 1 diabetes to live long, healthy lives with minimal complications.
For more information about diabetes management and the latest clinical guidelines, visit the American Diabetes Association Professional Resources and the Endocrine Society. Additional support and education resources are available through ADCES (Association of Diabetes Care & Education Specialists), JDRF, and Beyond Type 1.